74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Veru Inc
Closed
0.57 -8.06
Overview
Share price change
24h
Min
0.56
Max
0.61
Income | -415K -8.9M |
|---|---|
EPS | -0.071 |
Profit margin | -128.154 |
Employees | 210 |
EBITDA | -3M -11M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +603.13% upside |
Next Earnings | 7 May 2025 |
|---|
Market Cap | 74M |
|---|---|
Previous open | 8.63 |
Previous close | 0.57 |
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Veru Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Veru Inc Forecast
Price Target
By TipRanks
603.13% upside
12 Months Forecast
Average 4.5 USD 603.13%
High 5 USD
Low 4 USD
Based on 2 Wall Street analysts offering 12 month price targets forVeru Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Veru Inc
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
